<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920107-0115</DOCNO><DOCID>920107-0115.</DOCID><HL>   Technology:   Somatogen Gets U.K. Patent</HL><DATE>01/07/92</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   SMTG</CO><MS>TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>PATENTS (PAT)</NS><RE>COLORADO (CO)EUROPE (EU)NORTH AMERICA (NME)GREAT BRITAIN (UK)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   BOULDER, Colo. -- Somatogen Inc. said it received a patentin the U.K. for a genetically engineered blood substitute.   The hemoglobin-based blood substitute, which has beengenetically engineered to improve its ability to deliveroxygen to the tissues, was jointly developed by Somatogen andthe Medical Research Council in the U.K. A U.S. patentcovering the product has already been issued.</LP><TEXT>   The company said it has received clearance from the U.S.Food and Drug Administration to begin initial human safetytesting on the product. Somatogen said it hopes to apply tothe FDA for marketing approval by mid-1994.</TEXT></DOC>